Normosang (Human Hemin)

Human hemin supplies exogenous heme, which restores the normal feedback inhibition of the enzyme aminolevulinic acid synthase (ALAS) in the hepatic heme biosynthetic pathway. By suppressing ALAS activity, it decreases the production of aminolevulinic acid and porphobilinogen, limiting accumulation of neurotoxic intermediates that cause symptoms during an acute porphyria attack.

The dosing regimen for Normosang is individualized and determined by the prescribing physician based on the severity of the acute porphyria episode, patient weight, and clinical response. The product is supplied as a lyophilized powder for reconstitution and must be administered intravenously under medical supervision.

Safety data for human hemin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use during pregnancy or breastfeeding should only occur if the potential benefit justifies the potential risk to the fetus or infant, and it must be decided by the treating clinician.

To place an order, submit an inquiry on the product page at gnhindia.com specifying the required quantity of Normosang. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

The primary alternative to human hemin is the use of glucose loading, which can suppress ALAS activity but is less rapid and less effective in severe attacks. Other heme preparations, such as hemin arginate, have similar mechanisms. Normosang provides a standardized, injectable heme source with established efficacy for quickly terminating acute porphyria crises.

Normosang must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the reconstituted solution. Proper cold‑chain storage maintains product stability and potency until the point of use.

Normosang is supplied as a lyophilized powder that is reconstituted with the appropriate diluent immediately before use. The resulting solution is administered intravenously, typically through a peripheral or central line, under the supervision of qualified healthcare professionals. Infusion rates and monitoring are guided by the prescribing physician’s protocol.

Serious adverse reactions, although rare, include anaphylaxis, severe hemolysis, renal impairment, and thrombophlebitis at the infusion site. Patients should be monitored closely for signs of hypersensitivity, sudden drop in hemoglobin, kidney function changes, or vascular complications during and after the infusion.

Normosang is contraindicated in patients with known hypersensitivity to human hemin or any component of the formulation. Caution is advised in individuals with severe iron overload, uncontrolled renal failure, or active infection, and it should be avoided in patients for whom alternative, non‑heme therapies are appropriate unless specifically indicated by a physician.